Dosage &
Administration

A once-daily treatment with
dosing flexibility to meet your
patients’ needs1

Learn about how to start patients on Adhansia XR, titrate the dose, and provide ongoing monitoring.

Screening your patients prior to treatment

Before prescribing Adhansia XR, assess for1:

Presence of cardiac disease

  • Take a careful history
  • Investigate family history of sudden death or ventricular arrhythmia
  • Perform a physical exam

Risk of abuse

  • Check your state's Prescription Drug Monitoring Program to identify those at risk for misuse and patients obtaining controlled substances from multiple providers2
  • Use electronic prescribing for controlled substances to reduce diversion3,4
  • Advise patients and their caregivers:
    • That Adhansia XR is a federally controlled substance, and it can be abused and lead to dependence
    • Not to give Adhansia XR to anyone else, and to store Adhansia XR in a safe place (preferably locked)
    • To comply with laws and regulations on drug disposal

Note: Drugs known to have clinically important interactions with Adhansia XR are monoamine oxidase inhibitors, gastric pH modulators, antihypertensive drugs, and risperidone.1

Six strengths allow for titration to the optimal dose1

One capsule. Once daily.1

Recommended starting dose: 25 mg once daily

Six capsule strengths including 25mg, 35mg, 45mg, 55mg, 70mg, and 85mg
Capsules shown are not actual size.

Adhansia XR capsules may be1,5:

Swallowed whole or opened and the entire contents sprinkled onto a tablespoon of applesauce or yogurt.

How to administer Adhansia XR capsule

The entire mixture should be eaten, without chewing, immediately or within 10 minutes (if not eaten within 10 minutes after mixing, discard and do not store).

Note: The dose of a single capsule should not be divided. Patients should not take anything less than one capsule per day. In the event of a missed dose, do not administer later in the day or administer additional medication to make up for the missed dose.1

Initiation and titration

Recommended starting dose for patients 6 years or older: 25 mg once daily1

Switching to Adhansia XR

If switching from other MPH products:

  • Discontinue that treatment and titrate with Adhansia XR using the recommended titration schedule
  • Do not substitute Adhansia XR for other MPH products on a mg-per-mg basis because of different MPH base compositions and PK profile

Titrate in increments of 10 to 15 mg at intervals of ≥5 days1

Individualize dosage adjustments based upon assessment of clinical benefit and tolerability with careful consideration of the dose-related adverse reactions.

In short-term controlled trials:

  • In adults - Although efficacy was demonstrated at dosages of 100 mg daily, dosages >85 mg daily were associated with a disproportionate increase in the incidence of certain adverse reactions
  • In pediatric patients - Efficacy was demonstrated at dosages of 70 mg daily, but dosages ≥70 mg daily were associated with a disproportionate increase in the incidence of certain adverse reactions

MPH=methylphenidate; PK=pharmacokinetic.

Monitoring your patients throughout their treatment

After prescribing Adhansia XR1:

Dose reduction and discontiuation

  • Re-evaluate long-term use of Adhansia XR periodically, and adjust dosage as needed. Pharmacological treatment of ADHD may be needed for extended periods
  • Reduce the dosage or, if necessary, discontinue the drug if paradoxical aggravation of symptoms or other ARs occur. Adhansia XR should be periodically discontinued to assess patients' condition
  • Discontinue Adhansia XR if improvement is not seen after appropriate dosage adjustment over 1 month

Monitor for potential abuse and dependence

  • Monitor for signs of abuse and dependence, keep careful prescription records, and educate patients about abuse and diversion
  • Take note of increases in the amount of medication requested, or unscheduled or early refill requests2
  • Refer patients to receive appropriate treatment if they have developed a substance use disorder2

Note: Drugs known to have clinically important interactions with Adhansia XR are monoamine oxidase inhibitors, gastric pH modulators, antihypertensive drugs, and risperidone.1

ARs=adverse reactions.

Drugs having clinically important interactions with Adhansia XR1

Monoamine Oxidase Inhibitors

  • Clinical Impact: Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure
  • Intervention: Do not administer Adhansia XR concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment

Gastric pH Modulators

  • Clinical Impact: May change the release, PK profiles, and alter the pharmacodynamics of Adhansia XR
  • Intervention: Monitor patients for changes in clinical effect and use alternative therapy based on clinical response

Antihypertensive Drugs

  • Clinical Impact: Adhansia XR may decrease the effectiveness of drugs used to treat hypertension
  • Intervention: Monitor blood pressure and adjust the dosage of the antihypertensive drug as needed

Risperidone

  • Clinical Impact: Combined use of methylphenidate with risperidone when there is a change, whether an increase or decrease, in dosage of either or both medications, may increase the risk of EPS
  • Intervention: Monitor for signs of EPS

MAOIs=monoamine oxidase inhibitors; CNS=central nervous system; PK=pharmacokinetic; EPS=extrapyramidal symptoms.

PREVIOUS PAGERelease ProfileNEXT PAGEResponsible
Stimulant Use